A multi-institution phase i trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML).
Clinical Cancer Research.
Times cited: 40
VEGF-a stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between vegfr2 and ERK signaling.
Times cited: 123